Market capitalization | $1.49b |
Enterprise Value | $1.23b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.15 |
P/S ratio (TTM) P/S ratio | 7.44 |
P/B ratio (TTM) P/B ratio | 3.15 |
Revenue growth (TTM) Revenue growth | 3.53% |
Revenue (TTM) Revenue | $200.63m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
11 Analysts have issued a Schrodinger Inc forecast:
11 Analysts have issued a Schrodinger Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 201 201 |
4%
4%
|
|
Gross Profit | 131 131 |
14%
14%
|
|
EBITDA | -201 -201 |
24%
24%
|
EBIT (Operating Income) EBIT | -206 -206 |
24%
24%
|
Net Profit | -201 -201 |
404%
404%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.
Head office | United States |
CEO | Ramy Farid |
Employees | 867 |
Founded | 1990 |
Website | www.schrodinger.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.